Able-bodied person
Conditions
Interventions
Group A (Ascophyllan HS): 6 cases
Ascophyllan HS: 20 mg [20%] of ascofiran per tablet
One tablet once a day (between 11 am and 1 pm after lunch) for 28 consecutive days
Group P (placebo): 6 cases
One
Ascophyllan
Sponsors
Mizuno Shohei
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 20 to 60 years of age with no subjective symptoms (symptoms caused by any disease). Drinking habit less than 3 times a week, up to 180 ml of sake (beer: 500 ml, wine: 180 ml, shochu: 110 ml, whiskey: 60 ml). Normal liver and kidney function within the last year. Body Mass Index: greater than 16 and less than 25. Written explanation and written consent have been obtained. Employees in Aichi Medical University or their referrals. Usually one bowel movement within 3 days.
Exclusion criteria
Exclusion criteria: Currently receiving drug therapy. Currently suffering from a chronic disease (cardiac, pulmonary, renal, gastrointestinal, inflammatory, etc.) Invasive cancer within the last 5 years. Non-invasive cancer within the last 1 year. Smoked within the last year. Taken health foods, supplements, or vitamins containing ascophyllan within the last 2 weeks. Pregnant or breastfeeding women. History of hypersensitivity to supplements containing ascophyllan. Student at Aichi Medical University. Inappropriate by the study investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in NK cell activity with oral ascophyllan HS (29th day of the study) | — |
Secondary
| Measure | Time frame |
|---|---|
| The difference in the number of T cells, B cells, and plasmacytoid dendritic cells by oral administration of ascophyllan HS (up to 43 days after the start of the study) The difference in surface antigen expression on NK cells, T cells, B cells, and plasmacytoid dendritic cells by oral administration of ascophyllan HS (up to 43 days of the study) Associated toxicity after initiation of oral administration of ascophyllan HS (up to 43 days of the study) The differences in expression of inflammatory cytokines after oral administration of ascophyllan HS (up to 43 days of the study) The differences in HDL-C, LDL-C, triglycerides, glucose, HbA1c, and glycoalbumin with oral administration of ascophyllan HS (up to 43 days of the study) Percentage of weight gain or loss due to oral administration of ascophyllan HS (up to 43 days of the study) Changes in fecal microflora due to oral administration of ascophyllan HS (up to 43 days of the study) Changes in the presence and severity of general malaise, fever, cough, sore throat, and active infection (from day 44 to day 58 of the study) | — |
Contacts
Public ContactShohei Mizuo
Aichi Medical University Hospital
Outcome results
None listed